(Q26773381)

English

Combination of Intravesical Chemotherapy and Bacillus Calmette-Guerin Versus Bacillus Calmette-Guerin Monotherapy in Intermediate- and High-risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-analysis

scientific article

In more languages

Statements

scholarly article

0 references

2 references

20 June 2019

14 September 2020

comparative study

1 reference

systematic review

2 references

based on heuristic

inferred from title

2 references

based on heuristic

inferred from title

Combination of Intravesical Chemotherapy and Bacillus Calmette-Guerin Versus Bacillus Calmette-Guerin Monotherapy in Intermediate- and High-risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-analysis (English)

0 references

bladder neoplasm

3 references

20 June 2019

29 May 2020

14 September 2020

2 references

14 September 2020

1 reference

author name string

Jianfeng Cui

1

0 references

Wenbo Wang

2

0 references

Shouzhen Chen

3

0 references

Pengxiang Chen

4

0 references

Yue Yang

5

0 references

Yunliang Guo

6

0 references

Yaofeng Zhu

7

0 references

Fan Chen

8

0 references

Benkang Shi

9

0 references

language of work or name

0 references

publication date

January 2016

0 references

1 January 2016

5 references

3 April 2019

22 April 2019

20 June 2019

29 May 2020

14 September 2020

4 references

3 April 2019

22 April 2019

20 June 2019

14 September 2020

95

0 references

3

0 references

e2572

0 references

copyright license

Creative Commons Attribution 4.0 International

5 references

Europe PubMed Central

3 April 2019

Europe PubMed Central

22 April 2019

Europe PubMed Central

20 June 2019

Europe PubMed Central

29 May 2020

Europe PubMed Central

14 September 2020

copyright status

0 references

on focus list of Wikimedia project

0 references

Cancer statistics, 2015

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4998288

7 April 2017

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4998288

7 April 2017

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4998288

7 April 2017

Practical methods for incorporating summary time-to-event data into meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4998288

7 April 2017

Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4998288

28 September 2017

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4998288

28 September 2017

Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4998288

28 September 2017

A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4998288

28 September 2017

Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and [...]

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4998288

28 September 2017

Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study wit

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4998288

28 September 2017

Aggregate data meta-analysis with time-to-event outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4998288

28 September 2017

Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 t

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4998288

28 November 2018

Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4998288

28 November 2018

Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4998288

28 November 2018

Florida bladder cancer trends 1981 to 2004: minimal progress in decreasing advanced disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4998288

28 November 2018

Random-effects model for meta-analysis of clinical trials: an update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4998288

28 November 2018

Sequential bacillus Calmette-Guerin and epirubicin versus bacillus Calmette-Guerin alone for superficial bladder tumors: a randomized prospective study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4998288

28 November 2018

The value of perioperative mitomycin C instillation in improving subsequent bacillus calmette-guerin instillation efficacy in intermediate and high-risk patients with non-muscle invasive bladder cancer: a prospective randomized study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26817914

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26817914

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maximizing intravesical therapy options: is there an advantage to the administration of perioperative mitomycin C prior to an induction course of BCG?

1 reference

https://pubmed.ncbi.nlm.nih.gov/26817914

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26817914

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a ra

1 reference

https://pubmed.ncbi.nlm.nih.gov/26817914

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[EAU Recommendations 2001. "Guidelines on bladder cancer"]

1 reference

https://pubmed.ncbi.nlm.nih.gov/26817914

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/26817914

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Effect of Ofloxacin on Bacillus Calmette-Guerin Induced Toxicity in Patients With Superficial Bladder Cancer: Results of a Randomized, Prospective, Double-Blind, Placebo Controlled, Multicenter Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26817914

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/26817914

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1097/MD.0000000000002572

0 references

PMC publication ID

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q26773381&oldid=1517221739"